Regular use of illegal drugs is suspected to cause cognitive impairments. Two substances have received heightened attention: 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’) and δ-9-tetrahydrocannabinol (THC or ‘cannabis’). Preclinical evidence, as well as human studies examining regular ecstasy consumers, indicated that ecstasy use may have negative effects on learning, verbal memory and complex attentional functions. Cannabis has also been linked to symptoms of inattention and deficits in learning and memory. Most of the published studies in this field of research recruited participants by means of newspaper advertisements or by using word-of-mouth strategies. Because participants were usually aware that their drug use was critical to the research design, this awareness may have caused selection bias or created expectation effects. Focussing on attention and memory, this study aimed to assess cognitive functioning in a community-based representative sample that was derived from a large-scale epidemiological study. Available data concerning drug use history allowed sampling of subjects with varying degrees of lifetime drug experiences. Cognitive functioning was examined in 284 young participants, between 22 and 34 years. In general, their lifetime drug experience was moderate. Participants completed a neuropsychological test battery, including measures for verbal learning, memory and various attentional functions. Linear regression analysis was performed to investigate the relationship between cognitive functioning and lifetime experience of drug use. Ecstasy and cannabis use were significantly related to poorer episodic memory function in a dose-related manner. For attentional measures, decrements of small effect sizes were found. Error measures in tonic and phasic alertness tasks, selective attention task and vigilance showed small but significant effects, suggesting a stronger tendency to experience lapses of attention. No indication for differences in reaction time was found. The results are consistent with decrements of memory and attentional performance described in previous studies. These effects are relatively small; however, it must be kept in mind that this study focussed on assessing young adults with moderate drug use from a population-based study.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, DSM-IV, fourth ed. Washington, D.C: American Psychiatric Association.
2.
Anderson M (1992) Intelligence. In: AP Smith DM Jones (eds), Handbook of Human Performance, State and Trait, vol. 3. London: Academic Press, pp. 1–24.
3.
Beck AT Ward CH Mendelson M Mock J Erbaugh J (1961) An inventory for measuring depression.Arch Gen Psychiatry4: 561–571.
4.
Block RI Ghoneim MM (1993) Effects of chronic marijuana use on human cognition.Psychopharmacology110: 219–228.
5.
Bolla KI McCann UD Ricaurte GA (1998) Memory impairment in abstinent MDMA (“Ecstasy”) users.Neurology51: 1532–1537.
6.
Broadbent DE Cooper PF Fitzgerald P Parkes KR (1982) The Cognitive Failures Questionnaire (CFQ) and its correlates.Br J Clin Psychol21: 1–16.
7.
Cohen J (1988) Statistical Power Analysis for the Behavioural Sciences, second ed.Hillsdale, NJ: Erlbaum.
8.
Cole JC; Michailidou K; Jerome L; Sumnall HR; (2006) The effects of stereotype threat on cognitive function in ecstasy users. J Psychopharmacol 20: 518–525.
9.
Croft RJ Mackay AJ Mills ATD Gruzelier JGH (2001) The relative contributions of Ecstasy and Cannabis to cognitive impairment.Psychopharmacology153: 373–379.
10.
Dafters RI (2006) Chronic ecstasy (MDMA) use is associated with deficits in task-switching but not inhibition or memory updating executive functions.Alcohol Depend83: 181–184.
11.
Dafters RI Hoshi R Talbot AC (2004) Contribution of cannabis and MDMA (“Ecstasy”) to cognitive changes in long-term poly-drug users.Psychopharmacology173: 405–410.
12.
Dao-Castellana MH Samson Y Legault F Martinot JL Aubin HJ Crouzel C Feldman L Barrucand D Rancurel G Feline A Syrota A (1998) Frontal dysfunction in neurologically normal chronic alcoholic subjects: metabolic and neuropsychological findings.Psychol Med28: 1039–1048.
13.
Davies DR Taylor A Dorn L (1992) Aging and human performance. In: AP Smith DM Jones (eds), Handbook of Human Performance, State and Trait, vol. 3. London: Academic Press, pp. 25–62.
14.
Dumont GJH Verkes RJ (2006) A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers.J Psychopharmacol20: 176–187.
15.
Fein G Di Sclafani V (2004) Cerebral reserve capacity: implications for alcohol and drug abuse.Alcohol32: 63–67.
16.
Fisk JE Montgomery C Wareing M Murphy PN (2006) The effects of concurrent cannabis use among ecstasy users: neuroprotective or neurotoxic?Hum Psychopharmacol Clin Exp21: 355–366.
17.
Fletcher JM Page JB Francis DJ Copeland K Naus MJ Davis CM (1996) Cognitive correlates of long-term Cannabis use in Costa Rican men.Arch Gen Psychiatry53: 1051–1057.
18.
Fox HC Parrott AC Turner JJ (2001a) Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug.J Psychopharmacol1: 273–281.
19.
Fox HC Toplis AS Turner JJ Parrott AC (2001b) Auditory verbal learning in drug-free Ecstasy poly-drug users.Hum Psychopharmacol Clin Exp16: 613–618.
20.
Gouzoulis-Mayfrank E Daumann J (2006) The confounding problem of poly-drug use in recreational ecstasy/MDMA users: a brief overview.J Psychopharmacol20: 188–193.
21.
Gouzoulis-Mayfrank E Daumann J Tuchtenhagen F Pelz S Becker S Kunert H-J (2000) Impaired cognitive performance in drug-free recreational Ecstasy (MDMA) users.J Neurol Neurosurg Psychiatry70: 95–100.
22.
Grant I Gonzalez R Carey LC Natarajan L Wolfson T (2003) Non-acute (residual) neurocognitive effects of cannabis: a meta-analytic study.J Int Neuropsychol Soc9: 679–689.
23.
Green AR Mechan AO Elliott JM O’Shea E Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”).Pharmacol Rev55: 463–508.
24.
Gruber AJ Pope HG Hudson JI Yurgelun-Todd D (2003) Attributes of long-term heavy cannabis users: a case-control study.Psychol Med33: 1415–1422.
25.
Härting C Markowitsch HJ Neufeld H Calabrese P Deisinger K Kessler J (2003) Wechsler Gedächtnis Test – Revidierte Fassung. Deutsche Adaptation der revidierten Fassung der Wechsler Memory Scale.Berlin: Verlag Hans Huber.
26.
Hautzinger M Bailer M Worall H Keller F (1994) Beck-Depressions-Inventar (BDI). Bearbeitung der deutschen Ausgabe. Testhandbuch.Berlin: Verlag Hans Huber.
27.
Heubrock D (1991) Der Auditiv-Verbale Lerntest (AVLT) in der klinischen und experimentellen Neuropsychologie. Durchführung, Auswertung und Forschungsergebnisse.Zeitschrift für Differentielle und Diagnostische Psychologie13: 161–174.
28.
Klumb P (1995) Cognitive failures and performance differences: validation studies of a German version of the Cognitive-Failures-Questionnaire.Br J Psychol88: 29–38.
29.
Laux L Glanzmann P Schaffner P Spielberger CD (1981) Das State-Trait-Angst-Inventar. Theoretische Grandlagen und Handanweisung.Weinheim: Beltz Test GmbH.
Lehrl S Triebig G Fischer B (1995) Multiple choice vocabulary test MWT as a valid and short test to estimate premorbid intelligence.Acta Neurol Scand91: 335–345.
32.
Lezak MD (1976) Neuropsychological Assessment.New York: Oxford University Press.
33.
Lezak MD (1983) Neuropsychological Assessment, second ed.New York: Oxford University Press.
34.
Lieb R Isensee B von Sydow K Wittchen HU (2000) The Early Developmental Stages of Psychopathology Study (EDSP): a methodological update.Eur Addict Res6: 170–182.
35.
Lieb R Schütz CG Pfister H von Sydow K Wittchen HU (2002) Mental disorder in Ecstasy users: a prospective-longitudinal investigation.Drug Alcohol Depend68: 195–207.
36.
McCann UD Eligulashvili V Ricaurte GA (2000) (±)3,4-methylenedioxymethamphetamine (MDMA) induced serotonin neurotoxity: Clinical studies. Neuropsychopharmacology23: 113–126.
37.
McCann UD Mertl M Eligulashvili V Ricaurte GA (1999) Cognitive performance in ±3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) users: a controlled study.Psychopharmacology143: 417–425.
38.
McCann UD Szabo Z Scheffel U Dannals RF Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA (“ecstasy”) on brain serotonin neurons in human beings.Lancet352: 1433–1437.
39.
McCardle K Luebbers S Carter JD Croft RJ Stough C (2004) Chronic MDMA (ecstasy) use, cognition and mood.Psychopharmacology173: 434–439.
40.
Meyerhoff DJ Bode C Nixon SJ de Bruin EA Bode CJ Seitz HK (2005) Health risk of chronic moderate and heavy alcohol consumption: how much is too much?Alcohol Clin Exp Res29: 1334–1340.
41.
Morgan MJ (1999) Memory deficits associated with recreational use of “Ecstasy” (MDMA).Psychopharmacology141: 30–36.
42.
Morton J (2005) Ecstasy: pharmacology and neurotoxicity.Curr Opin Pharmacol5: 79–86.
43.
Osterrieth PA (1944) Le test de copie d’une figure complex: contribution à l’étude de la perception et de la mémoire.Arch Psychol30: 286–356.
44.
Parrott AC Less A Garnham NJ Jones M Wesness L (1998) Cognitive performance in recreational users of MDMA of “Ecstasy”: evidence for memory deficits.J Psychopharmacol12: 79–83.
45.
Parsons OA (1998) Neurocognitive deficits in alcoholics and social drinkers: a continuum?Alcohol Clin Exp Res22: 954–961.
46.
Parsons OA Nixon SJ (1998) Cognitive functioning in sober social drinkers: a review of the research since 1986.J Stud Alcohol59: 180–190.
47.
Pfister H Wittchen HU (1995) M-CIDI-Computerprogramm. München: Max-Planck-Institut für Psychiatrie, klinisches Institut.
48.
Piechatzek M Indlekofer F Daamen M Glasmacher C Lieb R Pfister H (submitted) Executive functions, working memory and impulsivity in a population-based sample of young adults with moderate or rare lifetime use of Ecstasy, Cannabis and Alcohol.
49.
Pope HG Gruber AJ Hudson JI Huestis MA Yurgelun-Todd D (2001) Neuropsychological performance in long-term cannabis users.Arch Gen Psychiatry58: 909–915.
50.
Raz A Buhle J (2006) Typologies of attentional networks.Nat Rev Neurosci7: 367–379.
51.
Reneman L de Win ML van den Brink W Booij J den Heeten GJ (2005) Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects.J Psychopharmacol20: 164–175.
52.
Reneman L Lavalaye J Schmand B de Wolff FA van den Brink W den Heeten GJ Booij J (2001) Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”).Arch Gen Psychiatry58: 901–906.
53.
Rey A (1941) L’examen psychologique dans les cas d’encéphalopathie traumatique.Arch Psychol28: 286–340.
54.
Rey A (1958) L’examen clinique en psychologie.Paris: Presse Universitaire de France.
55.
Ricaurte GA Yuan J McCann UD (2000) ±3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-induced serotonin neurotoxicity: studies in animals.Neuropsychobiology42: 5–10.
Rodgers J Buchanan T Scholey AB Heffernan TM Ling J Parrott AC (2001) Differential effects of ecstasy and cannabis on self-reports of memory ability: a web-based study.Hum Psychopharmacol Clin Exp16: 619–625.
58.
Rogers RD Robbins TW (2001) Investigating the neurocognitive deficits associated with chronic drug misuse.Curr Opin Neurobiol11: 250–257.
59.
Rollnick S Bell A (1991) Brief motivational interviewing for use by the nonspecialist. In: WR Miller S Rollnick (eds), Motivational Interviewing: Preparing People to Change Addictive Behaviors.New York: Guilford Press.
60.
Schifano F Di Furia L Forza G Minicuci N Bricolo R (1998) MDMA “Ecstasy” consumption in the context of poly-drug abuse: a report on 150 patients.Drug Alcohol Depend52: 85–90.
61.
Schuster P Lieb R Lamertz C Wittchen HU (1998) Is the use of ecstasy and hallucinogens increasing?Eur Addict Res4: 75–82.
62.
Schütz CG Chilcoat HD Anthony JC (1994) The association between sniffing inhalants and injecting drugs.Compr Psychiatry35: 99–105.
63.
Solowij N (1998) Cannabis and Cognitive Functioning.Cambridge: Cambridge University Press.
64.
Solowij N Stephens RS Roffman RA Babor T Kadden R Miller M (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment.JAMA287: 1123–1131.
65.
Spielberger CD (1983) Manual for the State-Trait Anxiety Inventory (STAI).Palo Alto, CA: Consulting Psychologists Press.
66.
Strote J Lee JE Wechsler H (2002) Increasing MDMA use among college students: results of a national survey.J Adolesc Health30: 64–72.
67.
Uhl A Kopf N Springer A Eisenbach-Stangl I Kobrna U Bachmayer S (2001) Handbuch Alkohol Österreich Zahlen – Daten – Fakten – Trends; 2. überarbeitete Auflage. Bundesministerium für soziale Sicherheit und Generationen (Hrsg.).
68.
van Zomeren AH Brouwer WH (1994) Clinical Neuropsychology of Attention.New York: Oxford University Press.
69.
Verbaten MN (2003) Specific memory deficits in ecstasy users? The results of a meta-analysis.Hum Psychopharmacol18: 281–290.
70.
von Sydow K Lieb R Pfister H Höfler M Wittchen HU (2002) Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults—a transient phenomenon? Results from a longitudinal community study.Drug Alcohol Depend66: 147–159.
71.
Wechsler D (1987) WMS-R: Wechsler Memory Scale—Revised (Manual).San Antonio, TX: The Psychological Corporation.
72.
WHO ASSIST Working Group (2002) The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility.Addiction97: 1183–1194.
73.
Wittchen HU Pfister H (1997) DIA-X-Interviews: Manual für Screening-Verfahren und Interview; Interviewheft Längsschnittuntersuchung (DIA-X-Lifetime); Ergänzungsheft (DIA-X-Lifetime); Interviewheft Querschnittuntersuchung (DIA-X-12 Monate); Ergänzungsheft (DIA-X-12 Monate); PC Programm zur Durchführung des Interviews (Längs- und Querschnittuntersuchung); Auswertungsprogramm.Frankfurt: Swets und Zeitlinger.
74.
World Health Organisation (1993) Tenth Revision of the International Classification of Diseases. ICD-10.Geneva: World Health Organisation.
75.
Yip JT Lee TM (2005) Effect of ecstasy use on neuropsychological function: a study in Hong Kong.Psychopharmacology179: 620–628.
76.
Zakzanis KK Young DA (2001) Memory impairment in abstinent MDMA users: a longitudinal investigation.Neurology56: 966–969.
77.
Zakzanis KK Young DA Radkhoshnound NF (2002) Attentional processes in abstinent methylenedioxymethamphetamine (ecstasy) users.Appl Neuropsychol9: 84–91.
78.
Zimmermann P Fimm B (2002) A test battery for attentional performance. In: M Leclercq P Zimmermann (eds), Applied Neuropsychology of Attention. Theory, Diagnosis and Rehabilitation, pp. 110–151.
